Skip to main content
4BASEBIO PLC logo

4BASEBIO PLC — Investor Relations & Filings

Ticker · 4BB ISIN · GB00BMCLYF79 LEI · 213800E2DX9EAIUNCB30 IL Manufacturing
Open in API
Filings indexed 102 across all filing types
Latest filing 2026-06-05 Proxy Solicitation & In…
Country GB United Kingdom
Listing IL 4BB

About 4BASEBIO PLC

https://www.4basebio.com/

4BASEBIO PLC is a biotechnology company specializing in the design and manufacturing of synthetic DNA for next-generation therapeutics and vaccines. The company provides high-purity, Good Manufacturing Practice (GMP) grade nucleic acid products, including its proprietary opDNA®, as a plasmid-free alternative to traditional methods. Its technology is engineered to accelerate development timelines, enhance safety, and improve manufacturing scalability for applications in genetic medicine, including mRNA vaccines, viral vector-based gene therapies, and gene editing. 4basebio's solutions aim to eliminate production bottlenecks and de-risk manufacturing for partners in the pharmaceutical and biotechnology sectors.

Recent filings

Filing Released Lang Actions
4basebio Plc - Notice of Annual General Meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice to shareholders of the upcoming Annual General Meeting, including the notice of meeting, explanatory notes on resolutions, proxy voting instructions, form of proxy, and related party transaction disclosure. It is intended to solicit shareholder votes and provide full information ahead of the AGM—not the AGM materials themselves or the final vote results. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-06-05 English
4basebio Plc - Director Dealing
Director's Dealing Classification · 85% confidence The document is an announcement that Dr. Amy Walker, a director and CEO, has acquired ordinary shares and includes the required Notification of Dealing table and details. This matches the definition of a Director’s Dealing (insider share transaction) rather than a company share buyback or other filing. Therefore, it should be classified as DIRS.
2026-05-22 English
4basebio Plc - Final Results and Notice of AGM
Earnings Release Classification · 92% confidence The document is a press‐style announcement dated 20 May 2026, titled “Final Results and Notice of AGM,” presenting audited financial highlights (revenue, loss, cash), operational highlights, post‐period events, and CEO/Chair commentary for the year ended 31 December 2025. It is an initial summary release of annual results, not the full Annual Report (which is stated to follow), and is formatted as a results announcement rather than a complete 10-K/AR. This aligns with an Earnings Release (ER) under the taxonomy. Therefore, it is classified as ER. FY 2025
2026-05-20 English
4basebio Plc - 4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
Regulatory Filings Classification · 85% confidence The document is a short press release announcing that 4basebio PLC has signed a Clinical Supply Agreement to support a Phase II clinical trial. It contains inside information notice under EU market abuse rules. There is no financial statement detail, dividends, or management changes. It does not present a formal report (none of the quarterly/annual report formats) but is a regulatory news announcement. This fits the “Regulatory Filings (RNS)” category.
2026-05-20 English
4basebio Plc - Appointment of Chief Financial Officer and Board Changes
Board/Management Information Classification · 90% confidence The document is a press release announcing the appointment of a new CFO and changes to the Board of Directors at 4basebio PLC, including stepping down of existing non-executive directors and their replacements. This clearly falls under announcements of management and board changes.
2026-05-14 English
4basebio Plc - 4basebio Launches Enzymatic ssDNA Platform
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the commercial launch of a new enzymatic ssDNA platform and upcoming conference presentation, distributed via the National Storage Mechanism and containing inside information. It does not contain financial statements, voting results, management changes, or other specific report content, so it falls under general regulatory announcement (RNS).
2026-05-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.